Page 224 - ebook HCC

PROGRAMME AND ABSTRACTSAND ABSTRACTS
GENEVA, SWITZERLANDA, SWITZERLAND
EASL HCC SUMMITHCC SUMMIT
223
222
222 PROGRAMME GENEV EASL 223
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C18
ITALY GIDEON FINAL ANALYSIS SORAFENIB-
TREATED PATIENTS: PROGNOSTIC VALUE OF
BASELINE CHARACTERISTICS AND STAGING
SYSTEMS

Salvatore D’Angelo , Vito Lorusso , Maria R. Piras , Domenico Sansonno , Results: Prognostic values of baseline characteristics and various staging systems for
3
2
1
4
Lydia Giannitrapani , Antonio Benedetti , Vincenzo Montesarchio , Adolfo F. Attili , median overall survival (OS) and time to progression (TTP) in the intent-to-treat population
7
5
8
6
Sergio Frustaci , Sandro Barni , Mario Pirisi , Daniela Carpani , (n=274) are shown in the table.
12
10
9
11
Giulia Magini , Bruno Daniele 14
13
1 Unità Fegato, AORN San G. Moscati, Avellino, UOC Oncologia Medica, IRCCS Conclusions: Final data of the Italian cohort of patients in the GIDEON study are
2
3
Ospedale di Bari, Bari, SC Gastroenterologia, Azienda Osp. G. Brotzu, Cagliari, consistent with the overall study results. As previously reported in other studies, baseline
4 Scienze Biomediche e Oncologia Umana. Sez Medicina Interna e Oncologia Clinica, characteristics and scoring/staging systems, including ECOG PS, Child-Pugh status,
5
Università degli Studi di Bari A.Moro, Bari, DiBiMIS, UOC Medicina Interna ed BCLC stage, CLIP and MELD scores, appear to be useful prognostic factors for OS.
6
Epatologia, AOUP Paolo Giaccone, Palermo, Clinica di Gastroenterologia, AUO Further analyses will be presented.
Ospedali Riuniti, Torrette di Ancona, UOC di Oncologia, AORN dei Colli - Ospedali
7
Monaldi-Cotugno-CTO, Napoli, UOC di Gastroenterologia, Policlinico Umberto I, Disclosure of Interest: D. Carpani: Bayer Employee; B. Daniele: Consultancy Bayer
8
9
Roma, SOC Oncologia Medica B, Centro di Riferimento Oncologico CRO, Aviano, Healthcare
11
10 Oncologia, AO Ospedale Treviglio - Caravaggio, Treviglio, SCDU Medicina Interna
12
1, AOU Maggiore della Carità, Novara, Medical Department, Bayer Spa, Milano,
13 USC Gastroenterologia, AO Papa Giovanni XXIII, Bergamo, U.O. Oncologia Medica,
14
Azienda Osp. Gaetano Rummo, Benevento, Italy
Corresponding author’s e-mail: daniela.carpani@bayer.com
Introduction: The GIDEON study (Global Investigation of therapeutic DEcisions in
CLINICAL POSTER ABSTRACTS countries. In Italy 278 patients were enrolled and results are reported here. CLINICAL POSTER ABSTRACTS
hepatocellular carcinoma and of its treatment with sorafeNib - NCT00812175) a large,
global, prospective, non-interventional study was conducted across 5 regions in 39
Aims: The primary aim was evaluate the safety of sorafenib in HCC patients in whom the
decision to treat with sorafenib was made in clinical practice
Methodology: Baseline characteristics were recorded at study entry; safety and efficacy
outcomes were collected during follow-up. Baseline characteristics and staging/scoring
systems were evaluated and analyzed in relation to patient outcomes.